

EPOXY-STEROIDAL ALDOSTERONE ANTAGONIST AND BETA-
ADRENERGIC ANTAGONIST COMBINATION THERAPY FOR
TREATMENT OF CONGESTIVE HEART FAILURE

5

ABSTRACT

09917403-072701

A combination therapy comprising a therapeutically-effective amount of an epoxy-steroidal aldosterone receptor antagonist and a therapeutically-effective amount of a beta-adrenergic antagonist is described for treatment of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites.

10

15 Preferred beta-adrenergic antagonists are those compounds having high potency and bioavailability. Preferred epoxy-steroidal aldosterone receptor antagonists are 20-spiroxane steroidal compounds characterized by the presence of a $9\alpha,11\alpha$ -substituted epoxy moiety. A preferred combination therapy includes

20 the beta-adrenergic antagonist metoprolol ((\pm)-1-(isopropylamino)-3-[p-(2-methoxyethyl)phenoxy]-2-propanolol succinate) and the aldosterone receptor antagonist epoxymexrenone.